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Quantification of the new immunosuppressant siroli-
mus (syn. rapamycin; Rapamune®) in whole blood by
chromatography is essential for its clinical use since no
immunoassay is available although monitoring is
mandatory. Here we report on a rapid and convenient
liquid chromatography (LC)-tandem mass spectrome-
try method and describe our practical experience with
its routine use. 
Whole blood samples were hemolyzed and depro-
teinized using an equal volume (150 µl) of a mixture of
methanol/zinc sulfate solution containing the internal
standard desmethoxy-rapamycin. After centrifugation,
the clear supernatants were submitted to an on-line
solid-phase extraction procedure using the polymeric
Waters Oasis HLB® material, with elution of the extracts
onto the analytical column in the back-flush mode by
column switching. For analytical chromatography a 
RP-C18 column was used with 90/10 methanol/2 mM
ammonium acetate as the mobile phase. A 1:10 split
was used for the transfer to the mass spectrometer, a
Micromass Quattro LC-tandem mass spectrometry sys-
tem equipped with a Z-spray® source and used in the
positive electrospray ionization mode. The following
transitions were recorded: sirolimus, 931>864 m/z, and
desmethoxy-rapamycin (I.S.), 901>834 m/z. The analyti-
cal running time was 5 min, including on-line extraction. 
The method has a linear calibration curve (r>0.99;
range 1.6–50 µg/l) and is rugged and precise with
monthly CVs <7% at a sirolimus concentration of 13.1
µg/l in routine use; the instrumentation proved to be
reliable and required minimal maintenance. Clin Chem
Lab Med 2002; 40(1):40–45
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Introduction
Sirolimus (syn. rapamycin; Rapamune®, Wyeth-Ayerst,
Princeton, NJ, USA) is a newly introduced immunosup-
pressant consisting of a 3-membered macrolide ring. It
modulates the immune response by inhibiting the ac-
tivity of a regulatory protein critical to the coordination
of events required for cells to move from the G1 to the S
phase of the cell cycle; this is in contrast to cyclosporin
and tacrolimus which achieve their effects by inhibiting
calcineurin and reducing interleukin-2 expression. An
essential advantage of sirolimus compared to cal-
cineurin inhibitors, especially in renal transplant pa-
tients, is the absence of nephrotoxicity (1). Additionally,
sirolimus exerts antiproliferative effects and may re-
duce the incidence of graft vessel disease (2–4).
The necessity for the therapeutic monitoring of
sirolimus has meanwhile become evident and is re-
commended for all patients. Enteral resorption of the
drug is very poor and shows important inter-individual
variation. Sirolimus is extensively metabolized by the
hepatic cytochrome P450 system, with probably little
contribution of its metabolites to immunosuppressive
effects (5). A large number of common drugs may in-
crease (e.g. cyclosporin, calcium antagonists, macro-
lide antibiotics, prokinetika, H2-receptor antagonists) or
decrease (e.g anticonvulsants, tuberculostatica) siroli-
mus whole blood concentrations. While whole blood
trough concentration below approximately 6 µg/l is as-
sociated with an increased risk of organ rejection after
kidney transplantation (in combination with cy-
closporin), trough concentrations above approxi-
mately 15 µg/l are associated with myelosuppression
(predominantly thrombocytopenia) and hypercholes-
terolemia (6, 7). Pharmacological characteristics of
sirolimus have been extensively reviewed (7–10). 
During phase II and III clinical trials, an automated
immunoassay manufactured by Abbott (Abbott Labo-
ratories, Abbott Park, IL, USA) has been used for
sirolimus monitoring (11); this assay, however, is not
available any more. In consequence, the clinical intro-
duction of sirolimus – which has been meanwhile li-
censed for the treatment of renal transplant patients
and investigated in phase III clinical studies in heart
and liver transplant patients – at present critically de-
pends on the availability of suitable analytical methods
for therapeutic drug monitoring. 
Several HPLC methods for the determination of
sirolimus, employing either UV-detection or mass-spec-
trometry, have been published previously. Due to the
poor UV-absorption of sirolimus, quantification using
UV-detection is cumbersome and highly efficient sam-
ple clean-up is necessary (12–15). Liquid chromatogra-
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phy with single-stage detection by mass spectrometry
(LC-MS) overcomes the poor UV-absorption of the
sirolimus molecule but requires also efficient chromato-
graphic separation due to the limited specificity of this
detection principle (16–20). In contrast, liquid chro-
matography-tandem mass spectrometry (LC-tandem
MS) (syn. LC/MS/MS) offers a far higher specificity, so
that chromatography can be substantially simplified, re-
sulting in short analytical run times. However, an effi-
cient sample clean-up procedure is required in order to
prevent malfunctions of the LC-tandem MS system due
to clogging of capillaries and ion suppression effects.
Previously described methods for the quantification of
sirolimus in whole blood by LC-tandem MS employ off-
line solid phase extraction (11, 21, 22), solvent extraction
(23) or simple on-line solid phase extraction procedure
as reported by Volosov et al. (24). Here we report long-
term experience with an optimized LC-tandem MS
method with on-line solid-phase extraction; in contrast
to the latter method, a separate extraction column con-
taining a copolymer material is used and elution of the
analyte from the extraction column onto the analytical
column is done in a back-flush mode.
Materials and Methods
Chemicals
Sirolimus (mw 914.187) and 32-desmethoxy-rapamycin (AY-
24668-1; mw 884.161) used as the internal standard were a gift
from Wyeth-Ayerst Research (Princeton, NJ, USA). Stock so-
lutions were prepared in methanol (50 mg/l).
Zinc sulfate heptahydrate (Merck, Darmstadt, Germany)
was dissolved in water to obtain a zinc sulfate concentration
of 50 g/l; a precipitation solution was made of methanol and
this zinc sulfate solution by mixing them in 4/1 proportion
(v/v). Ammonium acetate was from Merck (Darmstadt, Ger-
many); a 200 mM stock solution was made in water for prepa-
ration of the mobile phase. Methanol and water were of HPLC
grade (Baker, Deventer, The Netherlands). 
Instruments
The Waters Alliance 2690 HPLC separation module (Waters,
Milford, USA) consisting of an autosampler, a gradient pump
and a column oven was used, coupled with a split of approxi-
mately 1:10 to a Micromass Quattro LC-tandem MS system
equipped with a Z-spray® source (Micromass, Manchester,
UK). An additional isocratic HPLC pump was from Merck Hi-
tachi (model L-6000; Merck Darmstadt, Germany). 
Standards and samples
The stock calibrator was prepared by spiking a drug-free he-
molyzed whole blood pool with the sirolimus stock solutions
to a concentration of 50 µg/l; after careful mixing and
overnight equilibration additional working calibrators were
made by serial dilution (25–12.5–6.25–3.1–1.6 µg/l), frozen at
–70 °C and used in each series together with a zero-calibrator.
Sample preparation
A semi-automated two-step sample preparation protocol con-
sisting of a manual deproteinization step and an automated
(on-line) coupled-column solid phase extraction (SPE) proce-
dure was applied.
In 2.0 ml polypropylene cups (Eppendorf, Hamburg, Ger-
many) 150 µl of calibrators or carefully resuspended whole
blood samples, were precipitated with methanol/zinc sulfate
(50 g/l) 4/1 (v/v) containing desmethoxy-rapamycin (15 µg/l) as
an internal standard. After vigorous vortex mixing the sam-
ples were centrifuged in a benchtop centrifuge at 15000 g for
10 min; 150 µl of the clear supernatants were transferred into
the HPLC vials and placed in the autosampler.
For on-line solid phase extraction the Waters Oasis HLB®
column (50×1.0 mm; Waters, Milford, USA) was used together
with a six-port high-pressure switching valve (Rheodyne,
Rohnert Park, CA, USA) which was installed in the Waters
2690 separation module and controlled by the Micromass
Masslynx 3.4 software.
The operating procedure for the HPLC-integrated (on-line)
sample clean-up system consisted of three steps: first, 50 µl of
deproteinized sample were injected into the system by the au-
tosampler and transferred onto the Oasis HLB® extraction col-
umn. Here sirolimus was adsorbed, whereas potentially inter-
Figure 1 Column-switching scheme during the on-line ex-
traction procedure (W, waste; AC, analytical column). A: Load-
ing of the sample onto the extraction column and washing; B:
Elution from the extraction column onto the analytical column.
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fering matrix compounds were washed directly into the waste
by a mobile phase consisting of water/methanol, 95/5 (v/v) de-
livered at a flow rate of 4 ml/min for 1 min (Figure 1, valve po-
sition A). In parallel, the analytical column (Reprosil pur C18-
AQ, 125×2 mm; 5 µm, Maisch, Ammerbuch, Germany) was
equilibrated with methanol/2 mM ammonium acetate, 90/10
(v/v) with a flow rate of 0.5 ml/min. Following this on-line sam-
ple clean-up step, the six-port valve was switched to position
B; the extract was now eluted in the back-flush mode from the
Oasis HLB® column and transferred onto the analytical sepa-
ration column (mobile phase: methanol/2 mM ammonium ac-
etate, 90/10 (v/v); flow rate: 0.5 ml/min; time: 2 min). After the
transfer of sirolimus and the internal standard was completed,
the valve was switched back to position A and isocratic HPLC
separation was performed under the same chromatographic
conditions as described for the analyte transfer. Simultane-
ously, the Oasis HLB® extraction column was washed with
pure methanol at a flow rate of 4 ml/min for 1 min and subse-
quently re-equilibrated with water-methanol 95/5 (v/v). Both
the extraction and the analytical column were kept out at 35 °C
in a column oven.
The retention time of sirolimus and the internal standard,
respectively, was approximately 2.9 min, a complete analysis
cycle including SPE and separation took 5 min.
Mass spectrometric conditions
Electrospray atmospheric pressure ionization in the positive
mode was used; the source parameters were tuned to obtain
the ammonium adduct ions of sirolimus and desmethoxy-ra-
pamycin (931.5 m/z and 901.5 m/z), respectively; the following
settings resulted in optimum ion yield: capillary voltage, 3.0
kV; cone voltage, 25 V; source temperature 80 °C; desolvation
temperature 230 °C at a nitrogen flow of approximately 630
ml/min and a nebulizer gas flow of approximately 75 ml/min.
The collision energy with argon as the collision gas was 20 V.
Under these conditions an intense daughter ion of 864.5 m/z
was obtained from sirolimus, and of 834.5 m/z from
desmethoxy-rapamycin. Thus, the following ion transitions
were used for multiple reaction monitoring (MRM) from
minute 1 to 5 after sample injection: sirolimus 931.5>864.5
m/z, and desmethoxy-rapamycin 901.5>834.5 m/z. The dwell
time in both MRM traces was 0.5 s, interchannel delay and in-
terscan delay were 0.15 s.
For quantification, the response of calibrator and serum
samples was calculated as the peak area ratio of the MRM
trace of sirolimus and the internal standard, respectively (sin-
gle smoothing with a window size of one scan; polynominal
type: linear; fit weighting: 1/×). 
Assay validation
To investigate the analytical recovery of the extraction proce-
dure and possible ion-suppression effects, the standard solu-
tions of each sirolimus and desmethoxy-rapamycin in wa-
ter/methanol (90/10) at three concentration levels (5, 10, and
50 µg/l) were introduced as a bolus into a continuous flow of
the mobile phase by the built-in high-pressure valve of the MS
system; for comparison, whole blood calibrator samples, pre-
pared by spiking to the same concentrations as the standard
solutions (5, 10, and 50 µg/l), were submitted to the complete
assay as ordinary samples using a splitless mode of introduc-
tion to the MS system. The experiments were carried out in
duplicate. Mean peak areas of the respective MRM traces of
the analytes were compared between the two settings (direct
injection of standard solution vs. on-line extraction and HPLC
of spiked whole blood samples) to calculate a recovery rate
taking into account the dilution of the whole blood samples
during protein precipitation with methanol/zinc sulfate solu-
tion.
To study the linearity of the method, regression analysis of
the six calibrator samples run in four series was carried out;
the inaccuracy was determined for the calibrator samples by
comparing the recalculated concentrations with weighted tar-
get concentrations.
To investigate the imprecision of the method, three whole
blood pools were prepared from residual samples from pa-
tients treated with sirolimus, in a low, medium, and high con-
centration range, aliquoted and kept frozen at –70 °C. Analy-
ses were performed in four series over a 1-month period, each
determined in quadruplicate to calculate the total coefficient
of variation. The accuracy of the assay and its calibration was
assessed using calibrator samples provided by an interna-
tional proficiency testing scheme for sirolimus (Dr. D.W. Holt,
The Analytical Unit, St. George’s Hospital Medical School,
London, UK) over a 6-month period; the declared target con-
centrations and the results of the analyses were compared by
linear regression.
During routine use the whole blood pool from residual sam-
ples of sirolimus-treated patients was used in each series as a
precision control. Additionally, for quality control, the spiked
whole blood samples in a low, medium, and high concentra-
tion range (5.1, 10.2, and 20.4 µg/l) were regularly measured;
they were prepared from a stock solution that was separately
weighted-in; inaccuracy below 10% for the control samples
was defined acceptable for routine analysis.
To test the specificity of the method, 10 whole blood sam-
ples from transplant patients treated with cyclosporin,
tacrolimus, or mycophenolat mofetil were analyzed without
addition of the internal standard; generation of a signal in the
MRM traces of sirolimus and the internal standard, respec-
tively, was assessed. Moreover, 50 whole blood samples from
non-transplant intensive care unit patients – each treated with
several drugs – were analyzed in the same way.
Results
The mean recovery of the extraction procedure was
73% for sirolimus and 75% for desmethoxy-rapamycin
(internal standard) at a concentration of 7.5 µg/l, 77%
for sirolimus and 74% for desmethoxy-rapamycin at a
concentration of 15 µg/l, and 73% for sirolimus and
76% for desmethoxy-rapamycin at a concentration of
30 µg/l.
The assay proved to be linear over the full calibration
range (0–50 µg/l) with r>0.999 in four series of a pre-
routine validation. Recalculated concentrations of the
calibrator samples (mean) were as follows: calibrator
25 µg/l, 102.5%; calibrator 12.5 µg/l, 98.3%; calibrator
6.25 µg/l, 99.4%; calibrator 3.1 µg/l, 103.6%; calibrator
1.6 µg/l, 102.3%; the signal-to-noise ratio in the latter
sample was approximately 16:1.
Close agreement was found in 12 analyzed calibrator
samples obtained from an international proficiency
testing scheeme between found and target sirolimus
concentrations yielding the following results of linear
regression analysis: sirolimus found=1.02×sirolimus
target –0.3 µg/l (concentration range 0 to 60 µg/l).
The total coefficient of variation (n=16) was 8.2% for
the low pool (1.8 µg/l), 5.3% for the medium pool (13.1
µg/l), and 4.9% for the high pool (21.2 µg/l), with the pre-
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liminary therapeutic range 5 to 15 µg/l. For the whole
blood pool used for quality control in routine applica-
tion with sirolimus concentration of 13.1 g/l, 1-month
coefficients of variation were constantly below 7% and
control samples remained within the 10% inaccuracy
range.
In none of the samples from patients not treated with
sirolimus a specific peak signal was observed. Pure
multiple reaction chromatograms for sirolimus and the
internal standard were obtained from samples from
sirolimus-treated patients (Figure 2); no additional
peaks were found and the peak shape was identical to
that of calibrators with an equally low background sig-
nal. 
After 6 months of routine use and approximately
3000 clinical samples not a single instrument malfunc-
tion occurred, and the only maintenance performed
was a single cleaning of the ion source cone requiring
about 30 min; venting of the system was not necessary
for this maintenance thanks to a vacuum blocking
valve in the Micromass ion source. The analytical col-
umn was washed in back-flush with methanol over-
night once a week. The results of the analytical chro-
matography proved remarkably constant with respect
to retention time and peak shape. After more than 3000
analyses the Waters Oasis HLB® extraction column did
not show any signs of reduced extraction efficiency or
increased back pressure. 
Discussion
Here we describe a rapid LC-tandem MS method for
the determination of sirolimus in whole blood that ap-
plied atmospheric pressure electrospray ionization af-
ter manual sample deproteinization step followed by
on-line solid-phase extraction and liquid chromato-
graphic separation of the extracts. In contrast to the
previously described LC-tandem MS method (24) we
used a separate extraction column packed with a
copolymer material for on-line sample clean-up and
elution of the extracts from this extraction column in a
back-flush mode onto the series-connected analytical
column via column-switching. The method proved to
be efficient, linear, and accurate as well as free of rele-
vant ion suppression effects. In routine use the method
was precise and rugged, and the instrumentation was
found most reliable.
Compared to previously described methods, the
combination of LC-tandem MS technology with on-line
solid phase extraction enables quantification of
sirolimus with a considerably shorter hands-on time
(23) and running time (18). Thus, this method could be
applied to large series of clinical samples. 
Protein precipitation with a mixture of methanol and
zinc sulfate was most efficient and resulted in com-
pletely clear supernatants; protein precipitation was
combined in one step with the addition of the internal
standard. For the subsequent on-line solid-phase ex-
traction of the supernatants a copolymer material was
used (Waters Oasis HLB®). This macroporous material
is formed by equimolar polymerization of lipophilic 
n-vinylpyrrolidon monomers and hydrophilic divinyl-
benzol monomers and thus possesses hydrophilic as
well as lipophilic retention characteristics. The Oasis
HLB® extraction column (HLB for hydrophilic-lipophilic-
balance) can be operated at high flow rates (up to 4
ml/min) leading to an efficient sample preparation
within a short time. The extraction columns proved re-
markably stable with no apparent loss of extraction ef-
ficiency or increase in back-pressure after more than
3000 analyses. The highly efficient sample clean-up re-
sulted in stable chromatography results with minimal
background signal, constant retention times and peak
shape. Moreover, visual fouling on the electrospray
source components was minimal and cleaning (which
did not require the venting of the system) was neces-
sary only after extended working periods. 
The Z-spray® system of the Micromass instrument
yields stable mass-spectrometric results; this system
forces the ion beam into two orthogonal direction
changes by application of a counter-charge; in contrast,
Figure 2 Representative multiple reaction monitoring chro-
matogram of a whole blood sample from a heart transplant
patient (sirolimus concentration 7.8 µg/l). (a) m/z 931.5>864.5
represents the transition of sirolimus, (b) m/z 901.5>834.5 rep-
resents the transition the internal standard desmethoxy-ra-
pamycin.
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non-ionized compounds of the electrospray are not de-
viated and are thus effectively filtered out before enter-
ing the high-vacuum area of the mass spectrometer.
Despite the efficient two-step sample clean-up (pre-
cipitation and on-line extraction), chromatography
should not be omitted in LC-tandem MS analyses for
the sake of even shorter analytical running times since
ion suppression may arise from residual matrix com-
ponents (25, 26). 
The method described here can be easily modified to
quantify cyclosporin and tacrolimus simultaneously by
simply adding the respective multiple reaction moni-
toring traces; pre-routine validation revealed analytical
performance for these analyses similar to the determi-
nation of sirolimus; for logistical reasons, however, the
determination of these two immunosuppressants is
still performed by immunoassay in our laboratory.
Volosov et al. (24) have recently reported a LC-tan-
dem MS method for the quantification of sirolimus
which – similarly to our method – employs on-line
solid-phase extraction. In this method, however, no
separate extraction column was used. The analyte was
retained on a single HPLC column, matrix components
were washed with ammonium acetate buffer and after
post-column switching the analytes were eluted to the
mass spectrometry system (Sciex API 2000) by chang-
ing to the methanolic mobile phase. Direct comparison
of this method with our method described above
would be difficult. However, the principle applied in our
method (a separate extraction column requiring only
one additional HPLC pump) has the advantage that
practically matrix-free extracts are loaded onto the an-
alytical column; this explains our very constant chro-
matographic results. Also, the ion-suppression effects
from residual matrix components are further mini-
mized contributing to our favorable experience with
the method. 
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